Valuation : BioNTech SE

Market Cap 20.94B 24.3B 19.82B 17.97B 33.71B 2,321B 33.88B 235B 90.54B 1,181B 91.26B 89.26B 3,732B P/E 2026 *
-14.6x
P/E 2027 * -15.3x
Enterprise Value 9.57B 11.1B 9.06B 8.21B 15.4B 1,061B 15.48B 108B 41.37B 540B 41.7B 40.79B 1,705B EV / Sales 2026 *
5.3x
EV / Sales 2027 * 6.01x
Free-Float
96.06%
Yield 2026 *
-
Yield 2027 * -
1 day+0.42%
1 week-7.25%
Current month-5.02%
1 month+3.23%
3 months+6.74%
6 months+5.72%
Current year+2.27%
1 week 82.8
Extreme 82.8
89.2
1 month 78.5
Extreme 78.5
103
Current year 68.3
Extreme 68.3
105.7
1 year 68.3
Extreme 68.3
105.7
3 years 68.3
Extreme 68.3
124.9
5 years 68.3
Extreme 68.3
332
10 years 65.5
Extreme 65.5
395
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 59 01/01/2018
Chief Executive Officer 61 02/06/2008
Director of Finance/CFO - 01/07/2025
Director TitleAgeSince
Chairman 56 02/06/2008
Director/Board Member 69 02/06/2008
Director/Board Member 65 01/01/2018
Change 5-day change 1-year change 3-year change Capi.($)
+0.42%-7.25% - - 24.3B
-2.11%-1.68%+43.40%+95.58% 66.93B
-0.23%-4.45%+32.50%+77.58% 61.97B
+1.67%+2.47%-11.32%+392.05% 28.26B
+1.66%-1.90%+22.45%+13.51% 24.59B
+0.34%-6.78%-0.01%-14.59% 24.3B
+0.43%-3.37%+16.22%-17.48% 19.41B
-3.03%-2.29%+181.72%+333.47% 16.77B
-0.13%-4.57%-8.06%+529.46% 14.18B
+3.24%-0.31%-7.34%+833.51% 14B
Average +0.25%-2.95%+29.95%+249.23% 30.05B
Weighted average by Cap. -0.17%-2.83%+30.68%+172.67%

Financials

2026 *2027 *
Net sales 1.81B 2.1B 1.71B 1.55B 2.91B 200B 2.92B 20.32B 7.81B 102B 7.87B 7.7B 322B 1.81B 2.1B 1.72B 1.56B 2.92B 201B 2.93B 20.39B 7.84B 102B 7.9B 7.73B 323B
Net income -1.38B -1.6B -1.3B -1.18B -2.22B -153B -2.23B -15.5B -5.96B -77.73B -6.01B -5.87B -246B -1.31B -1.52B -1.24B -1.12B -2.11B -145B -2.12B -14.72B -5.66B -73.82B -5.7B -5.58B -233B
Net Debt -11.37B -13.19B -10.76B -9.76B -18.3B -1,261B -18.4B -128B -49.16B -641B -49.55B -48.47B -2,026B -10.03B -11.64B -9.5B -8.61B -16.15B -1,112B -16.23B -113B -43.38B -566B -43.72B -42.76B -1,788B
Logo BioNTech SE
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Employees
7,807
Date Price Change Volume
11/09/26 €83.20 +0.42% 10,182
10/09/26 €82.85 -1.13% 14,466
09/09/26 €83.80 -1.18% 11,731
08/09/26 €84.80 -4.45% 28,043
07/09/26 €88.75 -1.06% 19,243
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
83.34EUR
Average target price
102.47EUR
Spread / Average Target
+22.95%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!